Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas

Fig. 4

TMEFF2 methylation and mRNA expression levels in the TCGA dataset. a Boxplot of the TMEFF2 methylation level in different grades of primary gliomas (n = 1122). Kruskal-Wallis P < 0.001. b Boxplot of the TMEFF2 mRNA expression in different grades of primary gliomas (n = 1122). Kruskal-Wallis P < 0.001. c Negative association of TMEFF2 methylation with IDH1, ATRX, and TP53 mutations in primary gliomas. d Boxplot of the TMEFF2 methylation level in IDH1, ATRX and TP53 mutant/wild-type primary gliomas. e Boxplot of the TMEFF2 mRNA expression levels in IDH1, ATRX and TP53 mutant/wild-type primary gliomas. f Boxplot for TMEFF2 methylation level in IDH1/ATRX/TP53 combined mutant and non-combined mutant primary gliomas (n = 573). g Boxplot of the TMEFF2 mRNA expression in IDH1/ATRX/TP53 combined mutant and non-combined mutant primary gliomas (n = 588). h Boxplot for TMEFF2 methylation level in IDH1 mutant and IDH1 wild-type primary glioma patients’ tumor tissues. i Boxplot for TMEFF2 methylation level in IDH1/ATRX/TP53 combined mutant and non-combined mutant primary glioma patients’ tumor tissues. *P < 0.05, and ***P < 0.001

Back to article page
\